Oaktree Acquisition Corp. III Life Sciences (OACCU) Common Equity (2024 - 2026)
Oaktree Acquisition Corp. III Life Sciences' (OACCU) quarterly Common Equity came in at -$7.2 million in Q1 2026, down 10.85% YoY from -$8.1 million in Q1 2025, and down 6.74% on a QoQ basis from -$6.8 million in Q4 2025.
Oaktree Acquisition Corp. III Life Sciences (OACCU) Common Equity (2024 - 2026) Analysis & Trends
Oaktree Acquisition Corp. III Life Sciences (OACCU) has 3 years of Common Equity data on file, last reported at -$7.2 million in Q1 2026.
- Quarterly Common Equity fell 10.85% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.2 million (down 10.85% YoY) and the FY2025 annual result came in at -$6.8 million, down 11.45% from the prior year.
- Common Equity slipped to -$7.2 million in Q1 2026, from -$6.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$6.1 million in Q4 2024 to a low of -$7.2 million in Q1 2026.
- A 3-year average of -$6.6 million and a median of -$6.7 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity dropped 11.45% — and 2026, when it fell 10.85%.
- Tracing OACCU's Common Equity over 3 years: stood at -$6.1 million in 2024, then slipped by 11.45% to -$6.8 million in 2025, then decreased by 6.74% to -$7.2 million in 2026.
- The last three Common Equity figures came in at -$7.2 million (Q1 2026), -$6.8 million (Q4 2025), and -$6.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.49 Mn |
| Mar 31, 2026 | -7.23 Mn |
| Dec 31, 2025 | -6.77 Mn |
| Sep 30, 2025 | -6.76 Mn |
| Jun 30, 2025 | -6.54 Mn |
| Mar 31, 2025 | -6.52 Mn |
| Dec 31, 2024 | -6.07 Mn |